Series
Calendar: |
1/21/2009
|
Charles Vinson, PhD |
Arylstibonic Acids Inhibit B-ZIP DNA Binding: Where is the Specificity? |
10/1/2008
|
Wolfgang Sadee, Dr.rer.nat |
A Chemogenomics Approach to Discovery of Drug Targets, Novel Drugs, and Biomarkers in Cancer Chemotherapy |
4/30/2008
|
Lyuba Varticovski, MD |
Cancer Stem Cell: A Different Target? |
11/28/2007
|
Lee Ellis, MD |
Angiogenic Factors and Receptors in Colorectal Cancer: Challenging Existing Paradigms |
5/23/2007
|
Garth Powis, D.Phil |
Targeting the Stress Responses for Cancer Drug Discovery |
5/2/2007
|
Stephen W. Fesik, PhD |
CANCELLED--Bcl-2 Family Inhibitors for the Treatment of Cancer |
4/4/2007
|
M. Celeste Simon, PhD |
Hypoxia, HIFs and Stem Cells |
2/7/2007
|
James Hsieh, MD, PhD |
Proteolytic Signaling Pathways Led by Taspase 1 |
1/10/2007
|
Dr. Dean Tang |
Hierarchical Organization of Human Prostate Cancer Cells: Regulation of Self-Renewal |
5/31/2006
|
Charles D. Smith, PhD |
Protein Palmitoylation as a New Target for Cancer Chemotherapy |
4/26/2006
|
Yixian Zheng, Ph.D. |
Spindle Morphogenesis and Chromosome Segregation |
3/29/2006
|
James McAlpine, PhD |
The Genomics of Secondary Metabolite Biosynthesis as a Platform for Drug Discovery |
2/22/2006
|
John Condeelis, PhD |
The Invasion Microenvironment of Mammary Tumors |
1/25/2006
|
Dr. Pamela Silver |
Modulation and Redesign of Nuclear Networks in Disease |
9/28/2005
|
Bill J. Baker, PhD |
Palmerolides: Macrolides from the Antarctic Tunicate Synoicum Adareanum that Target V-ATPase |
3/23/2005
|
Richard J. Youle, PhD |
The Role of Bc1-2 Family Members in Programmed Cell Death |
2/9/2005
|
Ratna K. Vadlamudi, Ph.D. |
The Role of ER Coactivator PELP1 in Tumorigenesis |
1/26/2005
|
Lee Greenberger, Ph.D. |
Novel Antimicrotubule Agents: From Mechanism of Action to Clinical Trials |
1/12/2005
|
Hynda Kleinman, PhD |
CANCELLED--Role of Laminins in Angiogenesis and Tumor Growth |
12/8/2004
|
Steven K. Libutti, MD |
New Strategies for Studying and Targeting Tumor-Associated Vasculature |
10/13/2004
|
Roberto Pili |
Histone Deacetylase Inhibitors: Therapeutic Strategies for Solid Tumore |
5/26/2004
|
Dr. Louis Barrows |
Neoamphimedine, a Topoisomerase Drug with a Twist |
4/14/2004
|
Dr. William Hait |
Targeting the Calcium/Calmodulin Signal Transduction Pathway for Anticancer Therapy |
3/17/2004
|
Prof. James Gloer |
The Chemistry of Fungal Antagonism and Defense: A Useful Guide to the Discovery of New Bioactive Natural Products |
1/21/2004
|
W. Marston Linehan, MD |
Genetic Basic of Kidney: Opportunity for Development of Disease-Specific Therapy |
10/8/2003
|
Randall S. Johnson, Ph.D. |
Hypoxia: The Genetics of a Physiological Response |
9/24/2003
|
Dr. Marco Gottardis |
Developing New Hormonal Therapies in Prostate Cancer |
9/10/2003
|
Dr. John (Jay) Chiorini |
Identification of PDGFR as a Receptor for AAV5 Transduction |
4/16/2003
|
Heinz G. Floss, MD |
Genetic Tools for the Biosynthetic Structure Modification of the Maytansinoid Antitumor Agents |
3/19/2003
|
Dr. Donna Shewach |
Gemcitabine: An Effective Agent for Enhancing Radiation Therapy and Enzyme/Prodrug Gene Therapy |
3/5/2003
|
Dr. Steven Grant |
Development of Rational Antileukemic Strategies Combining Novel Signal Transduction and Cell Cycle Inhibitors |
2/25/2003
|
Dr. David Carlson |
Automated Platform for SNP's to Measure CYP1A1 and IB1 SNP's in the 60 Cell Lines |
2/19/2003
|
Dr. Marco Gottardis |
Developing New Hormonal Therapies in Prostate Cancer |
2/5/2003
|
Donald Small, MD, PhD, Johns Hopkins University School of Medicine |
Targeting FLT3 as Specific Therapy for Leukemia |
1/22/2003
|
Dr. Ivan N. Rich, HemoGenix LLC |
HALO-A High Throughput, Multifunctional Assay Platform for Hemotoxicity during Drug Development and Basic and Clinical Hematopoietic Research |
1/8/2003
|
Dr. Charles Tyson, SRI International |
In vitro Systems to Predict Hepatobiliary Toxicity |
12/11/2002
|
Karl Y. Hostetler, MD, University of California, San Diego |
1-O-Hexadecyloxpropyl-Nucleoside Phosphonates: Possible Use in Cancer Therapy |